FDA to review 7 popular peptides touted for weight loss, healing and longevity

The Food and Drug Administration is taking a closer look this week at seven unapproved peptide substances that have surged in popularity for their purported health benefits . At meetings scheduled for July 23 and 24 at the FDA’s White Oak Campus in Silver Spring, Maryland, the FDA’s Pharmacy Compounding Advisory Committee will consider whether to recommend adding seven peptide substances to the agency’s 503A Bulks List, which would allow them to be used in certain compounded prescription drugs.